Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even more robust results in the SURPASS trials, with participants losing up to 22.5% of body weight
More studies are needed to explore whether the GPX4-mediated activation of parthanatos is a widespread mechanism in other disease models, and how the lipid peroxidation involved in the regulation of parthanatos
Mail order shipments to deployed locations are unreliable
Factors like age, hormonal status, existing medical conditions, and concurrent medications all influence both the likelihood and severity of GLP-1 related dry mouth
In other words, its clear what the prescription medications are supposed to do, and at specific doses
Important caveat: Compounded medications are not the same as FDA-approved brand-name drugs